Clinical Trial Update: TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial assessing TIL Gean Therapy in combination with immunotherapy for advanced or metastatic refractory breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Immunotherapy (immunotherapy)
• TIL Gean Therapy (tumor-infiltrating lymphocyte therapy)

Snippet

Sponsor: Essen Biotech | Conditions: Breast Cancer, Breast Carcinoma | Phase 1, Phase 2 | Status: RECRUITING